Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2351 - 2375 of 15211 in total
Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder, a condition associated with distressing symptoms of urge urinary incontinence, urgency, and...
Approved
Investigational
Matched Description: … urinary frequency, and reduced quality of life of patients. ... bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency, and
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Iloperidone is a benzisoxazole and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. It is considered to be a second-generation antipsychotic drug with multiple receptor binding profile, although it shows high affinity towards 5-HT2A and dopamine D2 receptors. Iloperidone is currently used to...
Approved
Matched Description: … Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved ... ] with multiple receptor binding profile, although it shows high affinity towards 5-HT2A and ... [A263547] Iloperidone is currently used to treat schizophrenia and manic or mixed episodes associated …
Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. In 2006, the use of GBCAs was associated with the development...
Approved
Matched Description: … hardening of skin and subcutaneous tissues. ... vascularity in the central nervous system and the body. ... It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal …
Peppermint allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Herbs and Natural Products …
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase...
Approved
Matched Description: … These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. …
Matched Categories: … Triazole and tetrazole derivatives ... Metabolic Side Effects of Drugs and Substances …
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its...
Approved
Investigational
Withdrawn
Matched Description: … A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. ... (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products …
Matched Categories: … Hormones and Related Agents ... Antineoplastic and Immunomodulating Agents ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is...
Approved
Withdrawn
Matched Description: … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought ... Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and ... hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and
Matched Categories: … Alimentary Tract and Metabolism …
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.[A221451,A221456] The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are unable to...
Approved
Investigational
Matched Description: … [A189165] JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity ... joint symptoms and can limit range of motion in severe cases. ... comorbidities including cardiovascular disease and mental disorders. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Investigational
Matched Description: … development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric ... 36% for genotype 1 and 59% for genotypes 2-6 after 48 weeks of treatment. ... the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932. Carbamoylcholine was initially used as a treatment for migraines, induction of diuresis, and other parasympathetic effects. Carbamoylcholine was granted FDA approval on 28 September 1972.
Approved
Matched Description: … Carbamoylcholine was initially used as a treatment for migraines,[A226365] induction of diuresis,[A226370] and
Matched Categories: … Antiglaucoma Preparations and Miotics …
Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
Approved
Matched Description: … , Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum. ... Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical ... treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum …
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with...
Approved
Matched Description: … Golimumab binds and inhibits soluble and transmembrane human TNFα. ... Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies ... In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed...
Approved
Investigational
Matched Description: … human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and ... soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL ... [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate...
Approved
Investigational
Matched Description: … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations ... of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and ... Adagrasib targets KRASG12C, one of the most common KRAS mutations, at the cysteine 12 residue and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Approved
Investigational
Vet approved
Matched Description: … It is active against gram-negative bacteria and used for the treatment of gonorrhea. …
Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis . Newer dopamine receptor agonists such as quinagolide and DB00248 are...
Approved
Investigational
Matched Description: … Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido ... Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the ... It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand …
Matched Categories: … Genito Urinary System and Sex Hormones …
A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Approved
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada...
Approved
Investigational
Matched Description: … , physical, and cognitive effects. ... pain, diarrhea, bloody stools, and vomiting. ... It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction. The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in...
Approved
Investigational
Matched Description: … results in the destruction of these receptors and a reduction in electrical nerve impulses. ... autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and ... acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Emedastine is an antihistamine used in eye drops to treat allergic conjunctivitis.
Approved
Matched Categories: … Decongestants and Antiallergics …
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Approved
Matched Categories: … pargyline and diuretics ... MAO Inhibitors and Diuretics …
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
Approved
Investigational
Vet approved
Matched Description: … Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the …
Matched Categories: … Sulfur Compounds …
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a...
Approved
Investigational
Matched Description: … anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and ... Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is...
Approved
Investigational
Matched Description: … for causing hypotension or potentiating the effects of CNS depressants and anesthetics. ... Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity ... Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation …
Matched Categories: … Sulfur Compounds …
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT2A and HT2C receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the...
Approved
Investigational
Matched Description: … thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT2A and ... [A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia ... [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions …
Displaying drugs 2351 - 2375 of 15211 in total